Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
CBS8,
SOURCE Soligenix, Inc. At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits…